ABSTRACT: Advances in cardiac imaging have resulted in greater recognition of cardiac amyloidosis in everyday clinical practice, but the diagnosis continues to be made in patients with late-stage disease, suggesting that more needs to be done to improve awareness of its clinical manifestations and the potential of therapeutic intervention to improve prognosis. Light chain cardiac amyloidosis, in particular, if recognized early and treated with targeted plasma cell therapy, can be managed very effectively. For patients with transthyretin amyloidosis, there are numerous therapies that are currently in late-phase clinical trials. In this review, we address common questions encountered in clinical practice regarding etiology, clinical presentation, diagnosis, and management of cardiac amyloidosis, focusing on recent important developments in cardiac imaging and biochemical diagnosis. The aim is to show how a systematic approach to the evaluation of suspected cardiac amyloidosis can impact the prognosis of patients in the modern era.
to all forms of CA, there are 3 major precursor proteins causing CA, each with differing natural histories and therapies, including AL and ATTR because of a mutation (ATTRm) or wild type (ATTRwt). 7 
EPIDEMIOLOGY AND DELAYS IN DIAGNOSIS Is Cardiac Amyloidosis Rare?
AL-CA is a rare condition with an estimated prevalence of 8 to 12 per million. [8] [9] [10] There are ≈3000 newly diagnosed cases of AL amyloid per year in the United States, of which 30% to 50% have symptomatic cardiac involvement and 10% to 15% occur in association with multiple myeloma. 11 There are currently ≈10 000 individuals affected with AL in the United States, consistent with the definition of an orphan disease as one that affects <200 000 persons. The population prevalence of ATTR-CA is less certain, but recent data suggest that it is overlooked as a cause of common cardiovascular conditions in older people, including heart failure with preserved ejection fraction, low-flow aortic stenosis, and atrial fibrillation. 12, 13 Autopsy data have demonstrated that, among adults >80 years of age, 25% have transthyretin amyloid deposits in the myocardium. 14 Among patients with heart failure with preserved ejection fraction, autopsy data reveal amyloid deposits in 32% of those >75 years of age in comparison with 8% of those aged <75 years (8%). 15, 16 Emerging data using nuclear scintigraphy has suggested that 13% (95% confidence interval, 7.2%-19.5%) of patients hospitalized with heart failure with preserved ejection fraction may have ATTRwt-CA. 17 Some patients, however, have disease caused by mutations in the transthyretin (TTR) gene, and, although these are relatively rare, some genetic forms are endemic in particular geographic regions. The Val122Ile mutation, which almost exclusively affects individuals of African or Afro-Caribbean descent, has a population prevalence of 3% to 4%, 18 and, while clinical penetrance of this variant is incomplete in subjects up to 80 years of age, it is almost certainly underrecognized as a cause of heart failure. 19 Emerging data suggest that ATTR-CA, especially attributable to ATTRwt, is not uncommon and will become the most commonly diagnosed form of CA.
How Often Is the Diagnosis Missed or Delayed?
CA is often misdiagnosed and the delayed diagnosis has significant consequences for patients. In a survey of >500 patients with AL (37% of whom had cardiac involvement) the average time from initial symptoms to diagnosis was 2 years. A substantial proportion of patients (31.8%) reported seeing at least 5 physicians before receiving a diagnosis of amyloidosis. Cardiologists were consulted more often than hematologists, oncologists, or nephrologists, but were responsible for making the diagnosis in only 18.7% of cases. Similar data for ATTR-CA, albeit in much smaller populations, reveals that less than half of subjects were diagnosed within 6 months, mainly by cardiologists. 20 What Are the Impediments to Early and Accurate Diagnosis?
CA is a great pretender, often misdiagnosed as another condition or delayed in its recognition as a result of both physician-and disease-related factors. Optimum diagnosis and care requires multidisciplinary management (cardiology, neurology, nephrology, and hematology) but amyloidosis teams are relatively few. In addition, the absence of disease-modifying therapies for ATTR and the late presentation of AL-CA patients have contributed to a nihilistic attitude about the condition.
The main disease-related factor that hinders a correct and timely diagnosis is heterogeneity with respect to the cardiac phenotype, and systemic involvement, as well. The need for a histological demonstration of target organ amyloid infiltration has also delayed the diagnosis as the technique is restricted to referral centers with expertise in the performance of endomyocardial biopsy and requires skilled pathological analysis of obtained samples. Phenotypic variability of genetic forms of ATTR is also influenced by genetic heterogeneity, geography, endemic versus nonendemic aggregation, age, sex of the patient and transmitting parent, and probably amyloid fibril composition. [21] [22] [23] Patients also rarely report a family history because of the late presentation and incomplete penetrance.
In Whom Should One Consider Cardiac Amyloid?
The diagnosis of CA requires a high index of clinical suspicion. In the past, the presence of multiorgan involvement was overemphasized, resulting in consideration of the diagnosis only in the presence of extreme extracardiac findings such as macroglossia and periorbital purpura that, although specific, are present only in a minority of AL cases and absent in ATTR-CA. A number of diagnostic red flags (Table 1) in a patient with otherwise unexplained left ventricular hypertrophy or restrictive cardiomyopathy can foster the correct suspicion. A history of carpal tunnel syndrome in ATTR (particularly if bilateral in a male), atraumatic rupture of biceps tendon, unexplained neuropathic pain, orthostatic hypotension, and a diagnosis of hypertrophic cardiomyopathy after the sixth decade of life are useful clues.
Key Point
Increased awareness of cardiac amyloidosis is essential to reduce underdiagnosis and misdiagnosis, which is critical because prognosis worsens rapidly with advancing organ dysfunction.
The heterogeneity of systemic amyloidosis remains puzzling. Patients with the same type of amyloidosis, whether AL or ATTR, can have different patterns of organ involvement and different amounts of amyloid in the involved organs. Patients with systemic AL amyloidosis without heart involvement at diagnosis are likely to develop cardiac involvement if their culprit light chain proteins are not eliminated and if they live long enough. 24 The basis for the organ tropism of AL is not known. Studies of the immunoglobulin light chain genetic clones underlying AL indicate that the repertoire of light chain germline genes used in AL is restricted; 4 light chain variable region germline genes (IGKV1-16, IGLV6-57, IGLV2-14, IGLV3-1) account for two-thirds of cases, and there is tropism for the heart with IGLV2-14 and IGLV3-1, [25] [26] [27] [28] [29] although the mechanism is unknown. 30 The explanation for the differential involvement of the heart and peripheral nervous system in patients with ATTR is also unexplained.
What Is the Natural History of ATTR-CA?
ATTR-CA may be attributable to specific mutations that have a predominant involvement of the heart (Val122Ile, Leu111Met, Ile68Leu) or ATTRwt (Table 2 ). Ile68Leu and Leu111Met are mutations reported almost exclusively in Italy and Denmark, respectively, causing a severe cardiomyopathy at an early age with a malignant course. 22, [31] [32] [33] In the United States, ATTRwt followed by Val122Ile and Thr60Ala mutation forms are most common. 34 Original reports 7, 35, 36 suggested that ATTRwt-CA had a median survival of >5 years. However, recent reports [37] [38] [39] have demonstrated that outcomes are worse with median survivals of ≈3.5 years after initial evaluation. 40 These discrepancies are in part related to difficulty in defining when the disease begins. Initial manifestations of TTR deposits often include bilateral carpal tunnel syndrome, 41 which is found in ≈50% of individuals with ATTRwt-CA on average 5 to 7 years before the cardiac manifestations. Other manifestations include atrial arrhythmias and a progressive decline in effort tolerance, which are difficult to definitively attribute to amyloidosis because they occur commonly with advancing age. However, it is clear that ATTRwt-CA can manifest as early as the fifth decade of life. Cohort studies among subjects with ATTR-CA are predominately single-center reports. 37, 39, 42 One, multicenter, prospective cohort study, TRACS (Transthyretin Amyloid Cohort Study), 38 demonstrated in a small (n=29) population that mortality was high (29%) and differed between ATTRwt (22%) and Val122Ile (79%). Larger single-center studies have not confirmed this difference in survival and multivariate analyses of TRACS, and the THAOS registry (Transthyretin Amyloid Outcome Survey) data suggest that cardiac function and not the presence of a mutation was independently associated with mortality. 34, 42, 43 Progressive left ventricular dysfunction in ATTR-CA is mediated by physiological derangements that include reduction in chamber capacitance, declines in chamber contractility, and increases in arterial elastance. 43 Patients with ATTRwt-CA have impairments in peak Vo 2 and in a large series from the UK National Amyloidosis Center, a positive troponin T, presence of a pacemaker, and New York Heart Association class IV symptoms were associated at baseline with a worse outcome. 39 Clinically, as ATTR-CA progresses, blood pres- Table 1 .
Red Flags and Caveats in Cardiac Amyloidosis
A high index of suspicion is mandatory for the recognition of CA (ie, if you don't think of it, you won't diagnose it).
Cardiac amyloid should be suspected in any patient with heart failure, unexplained increased LV wall thickness, and a nondilated LV.
In a patient with a suspicion for HCM, look for the infiltrative features that suggest amyloid such as pericardial effusion, AV block, interatrial septal and valvular thickening, and apical sparring.
A distinctive sign of CA is the abnormal ratio between LV thickness and QRS voltages rather than low QRS voltages alone. The absence of low QRS voltages does not rule out a CA and up to 20% of subjects with CA can have electrocardiographic evidence of LV hypertrophy.
In an elderly man with unexplained symmetrical LV hypertrophy, especially in the absence of hypertension, always consider the possibility of ATTRwt-CA.
CA in an elderly patient with a monoclonal gammopathy is not necessarily attributable to AL: consider the possibility of ATTRwt and MGUS.
Longitudinal LV function can be severely depressed despite a normal LVEF, and the myocardial contraction fraction is often low, suggesting reduced global myocardial shortening.
Myocardial deformation is reduced in cardiac amyloidosis, but the apex is generally spared.
On cardiac MRI, both T1 signal abnormalities and marked extracellular volume expansion in patients with LV hypertrophy are strongly suggestive of CA.
LGE distribution is heterogeneous, and subendocardial enhancement is not the only pattern.
A history of bilateral carpal tunnel syndrome in a man with HCM-like phenotype on echocardiography is highly suggestive of ATTRwt-CA.
AL indicates immunoglobulin light chain; ATTR, amyloid transthyretin; ATTRwt, wild-type amyloid transthyretin; AV, atrioventricular; CA, cardiac amyloidosis; HCM, hypertrophic cardiomyopathy; LGE, late gadolinium enhancement; LV, left ventricle; LVEF, left ventricular ejection fraction; and MGUS, monoclonal gammopathy of undetermined significance.
sure falls because of a reduction in cardiac output and heart rate increases to compensate for a reduced stroke volume. Every 6 months, the mean 6-minute walk distance declined by 25.8 m, N-terminal probrain natriuretic peptide (NT-pro-BNP) increased by 1816 pg/mL, and left ventricular ejection fraction fell by 3.2%. 38 Cardiac cachexia is particularly common with ATTR-CA, potentially mediated, in part, by right heart failure, liver congestion, and possibly alterations in bowel flora.
Key Point
ATTR has been considered a neurological disease, but data from worldwide registries suggest that the heart is the main affected organ in at least half of the cases. ATTR cardiac amyloidosis is a progressive disorder associated with significant morbidity and mortality.
DIAGNOSING CARDIAC AMYLOIDOSIS
Is the ECG Useful for Identifying CA?
Classically, CA is characterized by low QRS voltage despite an increase in left ventricle (LV) wall thickness observed with noninvasive imaging. In contemporary series, however, the prevalence of low voltage varies with etiology, ranging from 60% in AL to 20% in ATTR. 44, 45 The absence of low QRS voltages does not, therefore, preclude CA, especially in patients with ATTRwt in whom LV hypertrophy or left bundle-branch block is present in up to 30% of patients. The hallmark of CA is the disproportion between LV wall thickness and QRS voltages. Although this relationship can be expressed in a relatively complex way, 46 it can be assessed more simply using LV wall thickness/total QRS voltage ratio. 47 Pseudoinfarction patterns, present in up to 70% of cases, can lead to an initial misdiagnosis of coronary heart disease. A significant number of patients develop conduction disease, and the presence of AV block in an older patient with LV hypertrophy should always prompt consideration of CA.
Is There a Laboratory Test to Diagnose CA?
As yet, no blood test can identify TTR oligomers and diagnose ATTR-CA. In contrast, in AL, serum and urine immunofixation and quantification of serum free light chains in combination have a 99% sensitivity for identifying the underlying substrate for AL-CA. It is important to note that an abnormal free light chain ratio alone is not specific for AL amyloidosis, because up to 5% of the population >65 years of age have a monoclonal gammopathy of undetermined significance. 48 This can lead to a misdiagnosis of AL-CA in elderly patients who actually have TTR-related CA and monoclonal gammopathy of undetermined significance (up to 10% of misdiagnosis even in referral centers). 49 In addition, free light chains are filtered by the glomeruli, with renal dysfunction resulting in increased serum concentrations. Renal dysfunction affects κ and λ free chains differently and a wider reference range for free light chain κ/λ ratio has been proposed for use in patients with advanced renal failure. 50 The broader κ/λ ratio normal ranges in patients with a low glomerular filtration rate makes the diagnosis of AL-CA more challenging in patients with renal failure. Although many patients with renal failure have increased LV wall thickness and serum β 2 -microglobulin can be associated with increased wall thickness, 51 β 2 -microglobulin amyloid deposition rarely causes meaning- ful cardiac dysfunction. 52 Natriuretic peptides tend to be particularly high in CA, often out of proportion from the hemodynamic burden. 53 Circulating light chains exert a direct toxic effect by modulating p38 mitogen-activated protein kinase, which can directly promote NT-pro-BNP expression. [54] [55] [56] Thus, for the same range of hemodynamic abnormalities, plasma levels of NT-pro-BNP are higher in AL than in ATTRwt and ATTRm. 53 An apoptotic effect can cause an elevation of troponins, sometimes leading to false diagnoses of acute coronary syndrome in patients with CA hospitalized for heart failure. Accordingly, the use of new blood tests such as the free light chain assay, NT-pro-BNP, and troponin in patients with new-onset dyspnea and no obvious etiology may enable the earlier diagnosis of AL-CA. This approach is particularly relevant to patients with preexisting clonal plasma cell diseases such as monoclonal gammopathy of undetermined significance or smoldering myeloma or in patients with unexplained increased wall thickness on echocardiography.
Should Everyone With TTR Cardiac Amyloidosis Have Gene Sequencing?
TTR gene sequencing is recommended in all cases of TTR-related amyloidosis because hereditary types of amyloidosis cannot be distinguished from acquired types on clinical grounds alone, and a family history indicating autosomal dominant inheritance is often absent because of incomplete and late disease penetrance. Thus, sequencing the transthyretin gene in conjunction with genetic counseling is recommended in cases in which hereditary TTR is proven by mass spectroscopy or suspected even with a negative profile on mass spectroscopy.
Do Laboratory Tests Predict Prognosis in CA?
There are well-established prognostic models in AL amyloidosis. Current staging systems for AL-CA are based on serum levels of NT-pro-BNP, cardiac troponin T, and the concentration of circulating free light chains. The combination of the 3 biomarkers constitutes the most powerful prognostic tool available in AL-CA and is the basis for the staging systems elaborated by the Mayo Clinic. 57 The scoring system assigns 1 point for each of the following: NT-pro-BNP ≥1800 pg/mL, troponin T ≥0.025 ng/mL, and difference between the κ and λ free light chains ≥18 mg/dL. Median survival of stage III patients was only 3.5 to 4.1 months. Patients with pronounced elevations of both NT-pro-BNP and troponin have a particularly poor prognosis. 58 Within stage III, NT-pro-BNP > 8500 pg/mL combined with a systolic blood pressure <100 mm Hg identifies patients with particularly high mortality (stage III B). NT-pro-BNP has also been shown to be a biomarker of clinical response and progression, and the change in its level after therapy is a surrogate for survival, 59 with a decrease associated with improved and an increase associated with worse overall survival 60 ( Figure 1) . Thus, even patients with advanced cardiac amyloid can achieve meaningful improvements in survival if the light chains are reduced and accompanied by a cardiac response reflected by a decline in NT-pro-BNP response, defined as a decrease in NT-pro-BNP of >30% and >300 ng/L assuming a baseline value were ≥650 ng/L. Such responses predict clinical outcome and survival independent of therapy type, treatment class, or regimen. 61 Emerging data suggest that cardiac biomarkers are also a useful prognostic marker of cardiac function in ATTR 40 
Key Point
In AL-CA, light chains can directly induce secretion of high levels of natriuretic peptides. NT-pro-BNP is a biomarker of clinical response, and progression of illness, as well; the change in its level after therapy is a surrogate for survival.
What Is the Role of Imaging Modalities in Diagnosing CA?
The diagnosis of CA should be systematic and directed toward the cause, and the presence of amyloid protein in the myocardium, as well. Laboratory tests, bone-tracer scintigraphy, genetic analysis, and tissue biopsy all have a place in achieving these goals. In clinical practice, cardiac imaging is relevant to CA in 3 scenarios: (1) differential diagnosis of hypertensive hypertrophic and restrictive cardiomyopathy (most common); (2) the evaluation of patients known or suspected to have systemic AL or familial TTR amyloidosis; and (3) in the presence of definite CA, to stage the disease and monitor the response to therapy. Cardiac imaging must be interpreted alongside other clinical findings, and different imaging techniques should be considered complementary. The question is not what the best examination is, but which is most useful and appropriate for each step of the diagnostic and therapeutic pathway (Table 3) .
What Are the Findings on Cardiac Ultrasound That Raise Suspicion of CA?
The echocardiographic findings of CA have been extensively reviewed elsewhere and are summarized in Figures 2 and 3 . [62] [63] [64] Nearly all are nonspecific, but, in context, they can be highly suggestive of CA. The major morphological abnormalities in patients with advanced disease are symmetrical thickening of the LV, thickening of the free wall of the right ventricle, and a small pericardial effusion. Classical signs also include thickening of the atrioventricular valves and interatrial septum and abnormal myocardial texture characterized as a speckled appearance, although the latter is less reliable when using har-monic imaging. Amyloidosis is the archetype for diastolic LV dysfunction, with findings dependent on the stage of disease. 65 Early cardiac involvement is often associated with impairment of relaxation that progresses to typical restrictive LV pathophysiology in advanced symptomatic disease. Analogous changes in right ventricular diastolic function occur in the right ventricular inflow, superior vena cava, and hepatic vein flow velocities. 66 CA is often listed as a cause of heart failure with preserved ejection fraction, but this underplays its impact on ventricular systolic performance. 7, 39, [67] [68] [69] [70] Although LV ejection fraction may be normal until the advanced stage of disease, reduction in peak systolic wall motion velocities, especially in the longitudinal axis, are present even in early disease. 71 In general, CA alters strain parameters to a much greater degree than other causes of LV hypertrophy and is characterized by a base-to-apex strain gradient (Figure 3 , Upper Right). 69, 70, 72 This is readily appreciated in parametric polar maps that show relative apical sparing of longitudinal strain, representing an important diagnostic clue differentiating CA from other cardiomyopathies. 69 In general, differentiating AL from ATTR-CA with echocardiography is not possible, but, on average, patients with AL-CA tend to be more restrictive, whereas those with ATTR-CA tend to have greater LV wall thickness. 7, 39, 47 What Is the Role of Cardiac MRI in Diagnosis?
Much of the structural information derived from cardiac MRI is similar to that obtained using echocardiography, but the ability to interrogate tissue composition with gadolinium-based contrast agents has led to an increase A, Mayo staging system for risk stratifying subjects with AL-CA in which 1 point is assigned for each of the following: NT-pro-BNP ≥1800 pg/mL, troponin T ≥0.025 ng/mL, and difference in serum-free light chains ≥18 mg/dL. Those with highest score have the worst prognosis.
57 B, Survival from the 3-month landmark of 300 patients with AL amyloidosis based on hematologic response. The proportion of stage III patients was not significantly different among the 4 hematologic response groups. CR indicates complete response; NR, no response; PR, partial response; VGPR, very good partial response; and py, person-year. 60 C, Prognostic relevance of cardiac response and progression criteria showing survival from the 6-month landmark of 377 patients with immunoglobulin light chain (AL) amyloidosis and baseline N-terminal natriuretic peptide type B (NT-proBNP) >650 ng/L according to NT-proBNP response and progression.
60 D, Survival according to NT-proBNP response in an ongoing phase 3 trial comparing melphalan-dexamethasone with melphalan-bortezomib-dexamethasone (NCT01277016).
in the frequency of diagnosis of CA. [73] [74] [75] [76] [77] [78] Gadolinium is a purely extracellular agent and does not enter intact cardiomyocytes. 73 In some cases of CA, there is a virtually pathognomonic appearance of global subendocardial late gadolinium enhancement in a noncoronary artery territory distribution with a dark blood pool. However, enhancement can also be diffuse and transmural or more localized and patchy. 73, 75, 79 False-negative studies can also arise for technical reasons when scans are nulled by using abnormal myocardium. 74 This latter problem is reduced by using phase-sensitive inversion recovery sequence that reduces the need for an optimal null point setting and makes scans less operator dependent. 73, 80 T1 mapping is a new magnetic resonance technique in which a quantitative signal from the myocardium is measured, before (native T1) or after contrast administration. 73, 76, 77 CA substantially increases native T1 and in AL and in ATTR-CA ( Figure 3 , Lower Right). T1 values are higher in AL-CA than in ATTR-CA, whereas the extracellular volume is higher in ATTR-CA than in AL-CA. 78 As native T1 requires no contrast administration, it can be used in patients with renal impairment and may be abnormal before the LV wall thickens. Combined, native T1 mapping and measures of extracellular volume postcontrast can delineate 3 aspects of CA, including amyloid burden or infiltration via measure of extracellular volume, edema via measure of native T1, and myocyte response via measure of intracellular volume. Such an approach can provide a richer understanding of the pathophysiological processes that may be used to monitor disease progression and response to therapy. Current limitations of the T1 imaging are the effect of confounding pathologies such as myocardial edema and platform-dependent variation in normal ranges for T1.
What Is the Role of Myocardial Scintigraphy in Making a Specific Diagnosis?
The 99mTc-phosphate derivatives, originally developed for bone imaging, were observed to accumulate in the early healing phase after acute myocardial infarction. 99mTc-PYP imaging was first described as a potential diagnostic test for CA in the early 1980s following reports describing increased cardiac uptake in patients with amyloid heart disease. [81] [82] [83] More recently in Europe, studies have evaluated the role of the tracer 99mTc-3,3-diphosphono-1,2-propanodicarboxylic in diagnosing CA ( Figure 3 , Lower Left). [84] [85] [86] Collectively, the data show that ATTR-CA is particularly avid for bone tracers, whereas uptake in AL-CA is either absent or only minimal. The explanation for this differential uptake is unknown, but it has been suggested that the preferential binding to ATTR may be a result of higher calcium content. Bone tracers seem to be useful for early identification of ATTR-CA and may more closely correlate with amyloid load than estimates from cardiac MRI. 87 In addition, there is also uptake in skeletal muscle, which may appear to suppress bone activity because of masking by extensive soft-tissue uptake. In selected patients, the specificity of bone tracer scintigraphy for ATTR CA is so high that this method can be considered a diagnostic standard (see below).
Can Positron Emission Tomography Be Used to Image and Quantify Amyloid?
18 F-Florbetapir is approved for imaging β-amyloid protein in the brain. Recent studies have shown that it is also taken up in the heart in patients with ATTR-CA and AL-CA (Figure 3 , Lower Right). Similar findings have been reported for another β-amyloid imaging agent 11C-PiB. 88 These agents hold promise for absolute quantification of amyloid burden.
How Can One Integrate the Various Imaging Modalities Into a Diagnostic Algorithm?
A consensus on the role of bone scintigraphy for noninvasive diagnosis of CA has emerged (Figure 4 ). If CA is suspected, blood and urine should be analyzed for evidence of a plasma cell dyscrasia and imaging with bone tracer considered if ATTR-CA is a possibility. If these tests are negative, then current evidence suggests that CA is very unlikely. 89 Cardiac MRI scanning may be used before nuclear scintigraphy as an aid to diagnosis, but a 10% to 20% false-negative (particularly in CA) and false-positive rate 78 (possibly more so in people of AfroCaribbean ancestry) for conventional contrast-enhanced scans means that it does not substitute for other tests. Until very recently, a tissue diagnosis was considered essential in all cases of suspected CA. However, in the setting of a positive 99mTc-phosphate scan without evidence for plasma clone on blood and urine testing, a diagnosis of ATTR-CA can be made without a biopsy. For those patients with evidence for a plasma cell dyscrasia, a histological diagnosis is still required because the presence of uptake on a 99mTc-phosphate scan is not 100% specific for ATTR-CA.
When and How Should Tissue Biopsy Be Undertaken?
The diagnostic accuracy of an extracardiac biopsy depends on the type of amyloidosis and on the examined tissue. In general, the yield of an extracardiac biopsy (abdominal fat pad, gingiva, skin, salivary gland, or gastrointestinal tract) is higher in AL than in ATTRm; the yield is low in ATTRwt. In AL-CA, the yield of a fat pad biopsy is >70% and is strongly associated with whole body amyloid load. In a series of 131 patients with ATTR-CA and a positive endomyocardial biopsy, fat aspiration was positive in 67% of ATTRm and only 14% of ATTRwt CA. 90 Thus, although a fat pad biopsy is a preferred initial site, a negative result is insufficient to exclude the diagnosis, and an endomyocardial biopsy should be performed.
How Does One Confirm the Precursor Protein Causing Amyloidosis?
The ultimate goal of a biopsy, in addition to documenting amyloid infiltration, is to provide a definite etiologic classification. Immunohistochemistry remains the most widely available method for fibril typing. Its diagnostic value is high in most cases of ATTR amyloidosis, but the Upper left, Subcostal 2D echocardiogram showing some of the typical findings in advanced cardiac amyloidosis. Biatrial enlargement, thickened interatrial septum (and valves), thickening of RV free wall, and concentric LVH and hyperechoic myocardial texture. Upper right, Apical 4-chamber peak systolic strain image illustrating relatively well-preserved apical strain with significant basal impairment. This is seen in the series of curves and the bull's-eye color-coded strain image. Lower left, Patient with atrial fibrillation and moderate to severely impaired LV function. Echocardiogram showed increased myocardial density and concentric LVH with moderate aortic stenosis. Cardiac MRI showed biventricular hypertrophy, moderate aortic stenosis, and diffuse fibrosis, in excess of that expected for LVH and aortic valve disease. A, Early whole body planar DPD image. B, Threehour delayed whole body planar image showing cardiac retention of racer and reduced bony uptake; Perugini Grade 2. C, D, and E, 2-chamber, short-axis, and 4-chamber PSIR LGE cardiac MRIs showing diffuse fibrosis. Images courtesy of Professor Elliott, University College London, UK. Lower right, Fused Florbetapir PET/MR imaging. A, Native T1 map shows high (>1400) values precontrast. B, ECV map, the ECV/interstitial space expansion is as high as blood. C, LGE image. There is differential fibrosis, between the core of the interventricular septum and the epi-and endocardial borders (white versus red arrows), and also in the lateral wall, which implies a nonuniform amyloid distribution. D, Fused Florbetapir PET/MR uptake with a LV basal septal predominance. Images courtesy of Dr Leon Menezes, University College London, UK. DPD indicates 99mTc-3,3-diphosphono-1,2-propanodicarboxylic; ECV, extracellular volume; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; PET, positron emission tomography; PSIR, phase-sensitive inversion recovery; and RV, right ventricular. monoclonal gammopathy showed strong TTR staining in the histological samples, whereas mass spectrometry demonstrated light chain amyloid in 5 of these 8 patients. 91 Mass spectrometric analysis of amyloid is the new gold standard for fibril typing. 6 This method involves laser microdissection and laser capture of amyloid using a microscope followed by tryptic digestion and tandem mass spectrometry. Computer algorithms match the peptides to a reference database, where amyloid fibril subtype can be identified. Frequently, mass spectroscopy can identify a mutant TTR genotype, although, when a mutation is not identified, gene sequencing may be necessary.
Key Point
Tissue diagnosis is required for AL amyloid and endomyocardial biopsy should be pursued if the index of suspicion is high despite a negative fat pad. Nuclear scintigraphy agents combined with assessment for monoclonal proteins are reducing the need for tissue confirmation in ATTR. Cardiac MRI characterization of myocardial tissue can be used to monitor disease progression and response to therapy.
STANDARD AND EMERGING THERAPIES FOR CA
Are There Specific Treatments for CA?
Diagnosis and clinical care have been held back by the erroneous belief that there are limited effective treatments for AL-CA and by the absence of disease-modifying therapy for ATTR-CA. It is now recognized that a reduction in the precursor proteins that forms amyloid fibrils is the key to improving prognosis in CA. Combination chemotherapy is effective in lowering free light chains in AL-CA, and orthotropic liver transplantation to remove the hepatic source of genetically variant amyloid-forming proteins either alone or in combination with cardiac transplant has a role in selected patients with ATTRm-CA. TTR stabilizers and silencers hold promise for managing all forms of ATTR-CA, and newer antifibrillar therapies aimed at reversing cardiac dysfunction are in clinical trials. The key determinant of the efficacy of therapy is the severity of disease at diagnosis. In advanced disease, therapy is poorly tolerated and often ineffective. 92 Multidisciplinary team management and supportive care is critical in controlling symptoms, optimizing nutritional status, maintaining cardiac function, and managing the toxicities of treatments. Collectively, therapeutic advances have begun to shift CA from a universally fatal disease to a manageable chronic condition.
AL CARDIAC AMYLOIDOSIS What Are the Goals of Therapy for AL-CA?
The toxic amyloid-forming light chains that cause AL are produced in the bone marrow and the clonal plasma cells in AL possess many of the same genetic abnormalities found in other plasma cell dyscrasias. [93] [94] [95] [96] The major difference between AL and myeloma is that in AL organ damage occurs because of the monoclonal light chains, whereas, in myeloma, the organ damage is largely attributable to cell mass. 97 Antiplasma cell treatments for AL have evolved from those used in myeloma, including steroids, high-dose melphalan, proteasome inhibitors, and immunomodulatory agents. 98 The goals of therapy in AL-CA are to eliminate the clonal plasma cells and provide optimal supportive care to address and control the side effects of therapy. Patients with advanced cardiac involvement cannot tolerate high-dose therapy The grading system for bone scintigraphy is grade 0, absent cardiac uptake; grade 1, mild uptake less than bone; grade 2, moderate uptake equal to bone; grade 3, high uptake greater than bone. AL indicates immunoglobulin light chain; AApoA1, apolipoprotein A-I; ATTR, amyloid transthyretin; DPD, 3,3-diphosphono-1,2-propanodicarboxylic acid; HDMP, hydroxymethylene diphosphonate; PYP, pyrophosphate; and TTR, transthyretin. Reprinted from Gillmore et al 89 with permission of the publisher. Copyright © 2016, American Heart Association, Inc.
with autologous stem cell transplantation (SCT), and, therefore, patient selection for SCT has become restrictive. 99, 100 Despite excellent hematologic response rates, patients with elevations of cardiac biomarkers who are poor candidates for SCT are also at significant risk even with standard bortezomib-based therapy with 40% dead within 2 years of diagnosis and only 20% of responders experiencing cardiac improvement by biomarker criteria. 101 However, when a response is achieved, survival can be meaningfully improved.
Is Halting Deposition of Amyloid the Only Treatment or Can Removal of Amyloid and Reversal of Organ Dysfunction Be Achieved?
Hematologic response and degree of cardiac involvement are the deciding factors regarding overall survival in systemic AL amyloidosis. 4 The categories of hematologic response with initial therapy in newly diagnosed patients are complete (CR, normal free light chain ratio and negative serum, and urine immunofixation), very good partial response (difference between involved and uninvolved free light chains <40 mg/L or <4 mg/dL), partial response (difference between uninvolved and involved free light chains decreased >50%), and no response. 60 The frequency of cardiac responses defined as a decline in NT-pro-BNP to <30% of baseline and of at least 300 pg/ mL in 374 newly diagnosed treated AL-CA patients were 57% with a CR, 37% with a very good partial response, 18% with a partial response, and 4% with no response 60 ( Figure 1 ). At 6 months after starting antiplasma cell chemotherapy, cardiac responses occurred in 26% and progression in 45% of patients, with 85% of responders and 30% of progressors still alive after 2 years. 60 Such data indicate that antiplasma cell chemotherapy, including the use of high-dose chemotherapy with SCT, does not enable reliable cardiac improvement for all patients, especially those with advanced cardiac involvement. Many patients with hematologic responses continue to have persistent cardiac dysfunction despite improved overall survival. After initial therapy, the median hematologic progressionfree survival is 1 to 4 years, depending on the type of initial therapy. The progression-free survival for the 25% of newly diagnosed patients who were candidates for SCT appears to be higher than that of patients receiving standard therapy with bortezomib-based combinations. Indeed, ≈80% of the long-term post-SCT survivors with CR have organ responses. 100 At hematologic relapse, the majority of patients have stage II or III chronic renal disease and stage II cardiac disease (see Figure 1) . 24 The unmet need for patients is therapy that reverses organ damage and dysfunction. 30 Several approaches are in clinical trials at this time, including 3 monoclonal antibody-based therapies that may enhance phagocytic clearance of amyloid deposits. The antiamyloid 11-1F4 monoclonal was used in a phase 1 trial (NCT02245867) in AL patients with relapsed refractory disease, and cardiac and gastrointestinal organ responses were reported in 3 of the first 6 patients treated. 102 Using a different approach in their phase 1 trial (NCT01777243), based on the fact that amyloid fibril deposits always contain the nonfibrillar normal plasma protein, SAP, investigators from the National Amyloidosis Center in the United Kingdom used a combination of 2 agents. The drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid, efficiently depletes SAP from the plasma but leaves some SAP in amyloid deposits that can be specifically targeted by therapeutic IgG anti-SAP antibodies, inciting an inflammatory multinucleated giant cell response. 103 In this phase 1 trial, whole-body scans using iodinated SAP demonstrated depletion of hepatic amyloid in 50% of patients with liver involvement. There were also reductions in in C3 and spikes in C-reactive protein, indicating ongoing inflammation. Patients with cardiac involvement were excluded from the trial. 104 The third, and furthest along in clinical development, is the antiamyloid monoclonal NEOD001 that binds to an epitope in amyloid fibrils. In a phase 1/2 trial (NCT01707264), previously treated AL patients who were in hematologic remission with biomarker evidence of on-going organ damage, received NEOD001 monthly. 105 There were no toxicities and organ responses were seen in the majority of both cardiac (57%) and renal (60%) patients. NEOD001 is now in a phase 3 trial for newly diagnosed patients with cardiac involvement (NCT02312206), in which patients receive bortezomib-based therapy and are randomly assigned to receive either NEOD001 or saline monthly.
What Are the Mechanisms of Therapeutic Efficacy (Reduction in Precursor Protein/Amyloid Production Versus Amyloid Clearance)?
Therapeutic efficacy in AL has 2 dimensions, survival and improvement in organ function. Hematologic response to therapy is measured in terms of the reduction or elimination of the clonal plasma cells that produce the culprit light chain protein. Patients who achieve a hematologic CR or very good partial response live longer than those who do not. 60 Improvement in organ function is measured with cardiac and renal biomarkers and, for patients with other organs involved, with a mix of examination and laboratory findings such as normalization of orthostatic symptoms and vital signs for patients with autonomic neuropathy or of liver span and alkaline phosphatase for those with hepatic involvement. 106 Patients who achieve cardiac biomarker responses live longer than those who do not. 59, 60, 107 Hematologic responses based on changes in the serum free light chain assay are validated surrogates for the impact of therapy on the clonal marrow cells. With elimination or near-elimination of the culprit light chain protein, patients usually experience improvement in organ function and in their quality of life. However, although hematologic response is necessary for organ response, it is not sufficient. 30 There is general consensus that both early cardiac death and survival with persistent organ damage are critical unmet clinical challenges.
What Factors Influence Treatment Decisions (Rapidity of Response, Toxicity, and Physiological Reserve)?
The initial evaluation of patients newly diagnosed with AL is focused on the extent of both cardiac and extracardiac organ involvement, physiological reserve, and the character of the clonal marrow plasma cells. 108 In a cohort of >800 patients from 6 countries, 26% were New York Heart Association class II or III, 25% chronic kidney disease stage III, and 15% chronic kidney disease stage IV or V; 50% were Mayo cardiac stage II with either troponin T or NT-pro-BNP above the threshold and 34% were cardiac stage III with both elevated; 19% had liver and 16% peripheral nervous system involvement. 60 
Who Is Eligible for SCT?
Eligibility criteria for high-dose therapy with SCT include age of <65, Karnofsky performance status of 80% or higher, adequate cardiac function (systolic blood pressure >90 mm Hg, ejection fraction >45%, troponin T <0.06 ng/mL, NT-pro-BNP <8500 pg/mL, or pulmonary artery saturation of >55%) and compensated or controlled orthostatic changes in blood pressure. 109 Patients who are Mayo cardiac stage III or chronic kidney disease stage IV are rarely eligible; young patients on hemodialysis, however, who are cardiac stage I or II are often eligible for SCT. Most patients are not eligible for SCT and receive bortezomib-based therapy with doses adjusted for frailty, impaired liver function, and New York Heart Association class. 110, 111 Bortezomib may not be the first choice of proteasome inhibitors for patients with peripheral neuropathy because of the risk of worsened neuropathy attributable to the drug; alternatives exist. 112 After SCT, consolidation is recommended for AL patients who do not achieve a CR (in myeloma post-SCT consolidation is recommended for all). 4, 113 For patients treated with bortezomib-based therapy, the lack of a hematologic response after 2 cycles is usually a signal to change therapy and, in most cases, bortezomib and dexamethasone will be retained but other agents such as melphalan or immune-modulatory drugs are added. 108 What Are the Data on Efficacy of Therapies?
The mix of therapies used to treat patients newly diagnosed with AL and the reported outcomes are recounted in online-only Data Supplement Table I . High-dose therapy with SCT and bortezomib-based combination chemotherapy are the 2 options used most frequently in the United States. 99 In the United Kingdom and European Union, however, SCT is used less often, and other regimens such as oral melphalan and dexamethasone or oral cyclophosphamide, thalidomide, and dexamethasone are commonly used. 98, 114, 115 Doses of agents in all of these regimens are often adjusted for age, frailty, renal and hepatic function, and New York Heart Association class.
Key Point
New targeted plasma cell therapies have rapidly expanded the treatment option for patients with AL cardiac amyloid, improving outcomes for patients with earlier-stage disease.
ATTR CARDIAC AMYLOIDOSIS What Are the Targets for Therapy in TTR?
Current treatment for ATTR-CA is focused on various stages in the TTR amyloid cascade, including silencing of TTR production, TTR stabilization, and amyloid clearance from tissues ( Figure 5) . [116] [117] [118] Because 95% of TTR protein is produced by the liver, orthotopic liver transplantation has been used in ATTRm to replace amyloidforming mutant with wild-type TTR and theoretically arrest amyloid formation. The majority of orthotopic liver transplantations for ATTRm amyloid are performed in patients with a primary neuropathic phenotype, most commonly the Val30Met variant. 119 Orthotopic liver transplantation is considered a preventative measure to forestall the development of the sensorimotor neuropathy or multiple organ involvement. Survival after liver transplantation in Val30Met patients is >50% at 20 years. 119 Because the liver function of TTR liver transplant recipients is otherwise normal, their livers have been transplanted into high-risk recipients (domino liver transplant), causing TTR amyloidosis in recipients several years later. 120 Although survival is prolonged by liver transplantation, 119 there is slowing but not arrest of cardiac dysfunction. This is attributed to deposition of wild-type TTR amyloid in the heart from the transplanted liver causing progressive cardiac dysfunction. Patients with fragmented ATTR fibrils (type A) developed heart failure after orthotopic liver transplantation, whereas those who had intact ATTR fibrils (type B) did not deteriorate to the same degree. 121 The scarcity of organ availability, the need for lifelong immunosuppression, and the relatively older age of affected subjects make transplantation a suboptimal option for treating ATTR-CA.
Both RNA interference and antisense oligonucleotides have been used to inhibit hepatic expression of amyloidforming TTR. These therapies capitalize on endogenous cellular mechanism for controlling gene expression in which small interfering RNAs or antisense oligonucleotides, mediates the destruction of target messenger RNA essential for TTR protein production. These agents cause a robust and durable reduction in genetic expression (knockdown) of TTR and retinol-binding protein. [122] [123] [124] Both methods of silencing have completed recruitment for phase 3 trials in ATTR peripheral neuropathy with results expected in 2017, but a phase 3 trial in ATTR cardiomyopathy was recently suspended with unexpected adverse impact on those receiving active treatment (online-only Data Supplement Table II) .
TTR stabilizers have demonstrated efficacy in family amyloid polyneuropathy, 125, 126 but their role in ATTR-CA is unknown. Diflunisal, a nonsteroidal anti-inflammatory drug, binds and stabilizes common familial TTR variants against acid-mediated fibril formation in vitro and has been tested in human clinical trials. 125 Use of diflunisal is controversial given the known consequences of chronic inhibition of cyclooxygenase enzymes, including gastrointestinal bleeding, renal dysfunction, fluid retention, and hypertension that may precipitate heart failure in vulnerable individuals. Tafamidis is a novel compound that binds to the thyroxinebinding sites of the TTR tetramer, inhibiting its dissociation into monomers 127 and blocking the rate-limiting step in the TTR amyloid-forming cascade ( Figure 5 ). Doxycycline disrupts fibril formation 128 and, when combined with the bile salt, tauroursodeoxycholic acid, demonstrated a synergistic effect on the removal of tissue TTR deposits in an animal model, leading to openlabel trials in humans. 129 Epigallocatechin gallate, the most abundant flavonoid in green tea, inhibits amyloid fibril formation in vitro, leading to open-label trials in ATTR-CA. 130, 131 What Are the Results of Recent Trials in TTR?
A majority of the trials completed to date have been small (<100 subjects), phase 2, open-label, intermediate duration (1-2 years) with primary end points being the Neuropathy Impairment Score in the Lower Limbs and quality of life for ATTR peripheral neuropathy, echocardiographic biomarkers, and 6-minute hall walk for ATTR-CA (online-only Data Supplement Table II) . Trials for neuropathy are further along than those for cardiomyopathy. Trials to date have demonstrated short-term efficacy limited to either a surrogate maker (TTR stabilization) or the absence or slowing of disease progression, albeit with no control group.
The only phase 3 trials completed to date involved administration of diflunisal 125 and tafamidis, 126, 132 both in family amyloid polyneuropathy. In the diflunisal trial, echocardiography demonstrated a prevalence of presumptive CA in >50% of these patients with family amyloid polyneuropathy, but analysis of echocardiographic variables including strain did not show significant differences with treatment, although statistical power was low. 133 Tafami- Figure 5 . Disease-modifying targets in TTR cardiac amyloidosis.
ALN indicates Alnylam Pharmaceuticals; CPHPC, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]
pyrrolidine-2-carboxylic acid; EGCG, epigallocatechin gallate; ISIS, ISIS Pharmaceuticals; mRNA, messenger RNA; SAP, serum amyloid P; siRNA, small interfering RNA; and TTR, transthyretin.
dis, in patients with early-stage ATTRm attributable to Val30Met, 126 slowed progression of neurological symptoms, and early treatment was associated with greater preservation of neurological function, 132 which was not confirmed in late-phase family amyloid polyneuropathy. 134 Thus, early administration of tafamidis seems to be important for its efficacy. In addition, all previous trials used a dose of 20 mg, but an 80-mg dose is being tested in an ongoing phase 3 trial, with biochemical data suggesting that a higher dose may be required for TTR stabilization. 135 Five-year safety data in a small cohort has been reassuring in that tafamidis was generally well tolerated at 20 mg, although efficacy data showed that few patients with ATTR-CA were clinically stabilized at 3.5 years.
What Therapies Are in Late-Phase Development?
At present, there is 1 clinical trial for ATTR-CA in phase 3 involving tafamidis. A second trial with revusiran, a small interfering RNA, was recently stopped, and the development of the drug was suspended. Both of these trials were placebo controlled with allocation to active therapy of ≈2:1 and a fixed study duration that encourages participation by subjects who have a progressive, life-threatening condition. Differences in study populations include a focus on ATTRm in the case of revusiran, whereas the other trial, ATTR-ACT (Transthyretin Amyloid Cardiomyopathy Tafamidis Study) enrolled both ATTRm and ATTRwt. The ATTR-ACT trial of tafamidis is expected to conclude in 2018.
Key Point
The biological process underlying ATTR-CA has led to the development of numerous therapies that are currently in late-phase clinical trials. A recent trial of a small interfering RNA for transthyretin in CA was stopped prematurely because of an unexpected worsening of subjects' clinical status.
CARDIAC REPLACEMENT THERAPY: TRANSPLANT AND VENTRICULAR ASSIST DEVICE
Is AL Amyloidosis a Contraindication to Cardiac Transplantation?
AL-CA was previously considered a contraindication to orthotopic heart transplant (OHT) because of concerns regarding worse long-term outcomes because of the amyloid involvement of other organs or the risk of recurrent amyloid in the graft. 136 However, the development of multiple therapies targeted at the monoclonal protein including high-dose chemotherapy with SCT has made long-term control of the plasma cell dyscrasia possible. Accordingly, series in selected patients for whom heart transplant was performed at experienced centers with established multidisciplinary collaborations followed by either stem cell transplant or ongoing chemotherapy have reported outcomes comparable to other subjects with restrictive cardiomyopathies. [137] [138] [139] [140] In addition, an analysis of UNOS data shows improved post-OHT survival in patients with CA, in part, because of improved patient selection including an increase in those with ATTR-CA. 140 The 1-year survival post-OHT in UNOS for CA (including both AL-CA and ATTR-CA) from 2010 to 2012 was 81.6%. Accordingly, current guidelines endorse consideration of selected patients with either AL or ATTR-CA. 141 What Additional Testing Is Required for Heart Transplant Evaluation?
The degree of organs involved is an important prognostic variable influencing the outcomes of patients with AL undergoing SCT. Accordingly, multiple other organ systems must be thoroughly assessed for the functional effect of amyloid and, if necessary, for the anatomic/histological degree of amyloid infiltration. Specific guidelines by the International Society for Heart Lung Transplantation have been published (see Table 4 ). 141 Do Outcomes Differ in Subjects With AL Versus TTR-CA Undergoing OHT?
Data from Columbia University Medical Center have shown better survival for ATTR-CA subjects (n=10) than AL-CA subjects (n=16) undergoing OHT with transplants performed from 1999 to 2008. However, a more contemporary series from Stanford has shown better survival in AL (n=10) than TTR (n=9) CA. 139 Multicenter data obtained as part of the International Consortium in Cardiac Amyloid Transplantation has demonstrated that outcomes of patients with CA do not differ statistically from those with AL in comparison with TTR. 142 How Should the Plasma Clone Be Managed in Patients With AL-CA Undergoing OHT?
Control of the underlying plasma cell dyscrasia is critical to successful outcomes in AL-CA. Data from International Consortium in Cardiac Amyloid Transplantation demonstrate that survival without recurrent amyloidosis post-OHT is higher in those who receive chemotherapy before OHT than those who did not receive chemotherapy.
How Can I Bridge My Patient With Advanced CA to an OHT?
The options for mechanical circulatory support as a bridge to OHT for CA patients is confounded by the small ventricular chamber size and increased wall thickness that increase the risk for suction events, right heart failure, and overall worse outcomes in very small series reported to date. 144 Survival with a ventricular assist device is strongly associated with LV end-diastolic diameter. 145 Other forms of circulatory support including intra-aortic balloon pump, biventricular assist device, or total artificial heart (the latter used given the need for biventricular support) have been used, although survival at 1 year is reduced if circulatory support is required. 146 A theoretical analysis using a cardiovascular simulation of a novel MicroVAD for CA has shown that sourcing of blood from the left atrium was not associated with suction, as assessed by declines in LV end-systolic volumes, but did lower left atrial pressure and increase cardiac output and blood pressure in subjects. 147 Whether such an approach can be effective in vivo in CA requires additional study.
Key Point
Although the overall goal is to eliminate the need for OHT in CA, advances in patient selection and available therapies have made intermediate-term outcomes of OHT in CA comparable to nonamyloid patients. 
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Circulation is available at http://circ.ahajournals.org. ·1.73 m -2 in the absence of decompensated heart failure or urinary protein excretion >0.5 g/24 h should prompt renal biopsy to assess the renal amyloid burden.
Coagulation
Factor X and thrombin time.
Patients with a severe (<25%) factor X functional deficiency have <50% survival after ASCT.
AL indicates immunoglobulin light chain; ASCT, autologous stem cell transplantation; CT, computed tomography; CXR, chest x-ray; eGFR, estimated glomerular filtration rate; ISHLT, International Society for Heart & Lung Transplantation; and OHT, orthotopic heart transplant.
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